Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms

ISSN： 0963-6048

Source： International Journal of Biotechnology, Vol.10, Iss.5, 2008-11, pp. : 416-440

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The life sciences are having a significant impact on the organisation and management of R&D in large pharmaceutical firms, as well as restructuring the markets for new therapeutic products. However, there is continuing scepticism about large firms' ability or inclination to build in-house capacity for biologics and extract value from the life sciences. This paper explores the effect of life science innovation on early and late-stage R&D, and considers the implications for strategic management and the transition of compounds through the middle stages of the R&D pathway. The analysis, which includes two company case studies, reveals that new life science technologies have had a marginal impact on late-stage R&D, but companies are exploring new organisational or translational models to better exploit the science and reduce the phase 2 attrition rates. Findings suggest that firms have the capability to adapt to a new innovation trajectory, but external pressures on strategic and organisational management will continue to determine the level and rate of success.